AI assistant
Aprea Therapeutics, Inc. — Director's Dealing 2021
Aug 27, 2021
35269_dirs_2021-08-27_db814981-acc4-4efe-a6c0-2e43131b33ec.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aprea Therapeutics, Inc. (APRE)
CIK: 0001781983
Period of Report: 2021-08-25
Reporting Person: Attar Eyal C. (SVP, Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-25 | Common Stock | F | 9032 | $3.98 | Disposed | 98968 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 172 | Indirect |
| Common Stock | 159 | Indirect |
Footnotes
F1: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 25,000 restricted stock units
F2: Net of 28 shares sold by account custodian to satisfy account minimum. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
F3: Net of 41 shares sold by account custodian to satisfy account minimum. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.